<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval</h1>

    <table>
      <tr><th>Ticker</th><td>PDSB</td></tr>
      <tr><th>Float</th><td>53.3 M</td></tr>
      <tr><th>IO</th><td>14.46%</td></tr>
      <tr><th>MC</th><td>36.0 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>This is a Form 8-K filed by PDS Biotech (PDSB) furnishing a press release announcing an amendment to the Phase 3 VERSATILE-003 trial protocol to use progression-free survival (PFS) as the primary endpoint for an interim analysis. The company states the PFS-based interim analysis is intended to support a potential accelerated approval pathway. The press release was furnished as an exhibit to the 8-K (Exhibit 99.1). The 8-K furnishes the announcement but does not include clinical outcome data in the filing.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Company amended Phase 3 VERSATILE-003 protocol to designate PFS as primary endpoint for interim analysis.</li><li>Company indicates the PFS-based interim analysis is intended to support a potential accelerated approval pathway.</li><li>Press release announcing the amendment was furnished on Form 8-K (Exhibit 99.1), making the information SEC-filed and public.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Form 8-K furnishes the press release but does not present clinical results or data within the filing.</li><li>Amendment to use PFS for interim analysis does not guarantee regulatory approval or accelerated approval.</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036126006229/0001140361-26-006229-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">PDSB â€¢ TradersLink AI News</div>
  </div>
</body>
</html>